Pegunigalsidase

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.

Journal: Orphanet journal of rare diseases

Published: November 12, 2025

A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease.

A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease.

Journal: Frontiers in immunology

Published: October 14, 2025

Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.

Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.

Journal: Journal of clinical medicine

Published: May 23, 2025

Progress and Challenges in the Treatment of Fabry Disease.

Progress and Challenges in the Treatment of Fabry Disease.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: April 09, 2025

Lysosomal storage diseases in North America: a comprehensive review of enzyme therapies and unmet needs.

Lysosomal storage diseases in North America: a comprehensive review of enzyme therapies and unmet needs.

Journal: Therapeutic advances in rare disease

Published: February 17, 2025

New Drugs Available for Fabry Disease.

New Drugs Available for Fabry Disease.

Journal: Kidney & blood pressure research

Published: December 30, 2024

Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease.

Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: November 04, 2024

Current status of the immunogenicity of enzyme replacement therapy in fabry disease.

Current status of the immunogenicity of enzyme replacement therapy in fabry disease.

Journal: Orphanet journal of rare diseases

Published: October 10, 2024

Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement.

Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement.

Journal: International journal of molecular sciences

Published: August 02, 2024

Plant molecular farming: a promising frontier for orphan drug production.

Plant molecular farming: a promising frontier for orphan drug production.

Journal: Biotechnology letters

Published: August 01, 2024

Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice.

Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice.

Journal: Advances in therapy

Published: July 11, 2024

What is confirmed in the treatment of Fabry's disease?

What is confirmed in the treatment of Fabry's disease?

Journal: Innere Medizin (Heidelberg, Germany)

Published: June 17, 2024

Showing 1-12 of 28

Last Updated: 04/28/2026